Xencor (XNCR) Stock Forecast, Price Target & Predictions
XNCR Stock Forecast
Xencor stock forecast is as follows: an average price target of $42.60 (represents a 98.42% upside from XNCR’s last price of $21.47) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
XNCR Price Target
The average price target for Xencor (XNCR) is $42.60 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $58.00 to $31.00. This represents a potential 98.42% upside from XNCR's last price of $21.47.
XNCR Analyst Ratings
According to 6 Wall Street analysts, Xencor's rating consensus is 'Buy'. The analyst rating breakdown for XNCR stock is 1 'Strong Buy' (16.67%), 5 'Buy' (83.33%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Xencor Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 14, 2024 | Etzer Darout | BMO Capital | $32.00 | $20.89 | 53.15% | 49.05% |
| Jun 14, 2024 | Gregory Renza | RBC Capital | $31.00 | $20.99 | 47.69% | 44.39% |
| Apr 16, 2024 | Kaveri Pohlman | BTIG | $38.00 | $20.11 | 88.96% | 76.99% |
| Oct 04, 2021 | Charles Zhu | Guggenheim | $54.00 | $35.52 | 52.03% | 151.51% |
| May 05, 2021 | Dane Leone | Raymond James | $58.00 | $40.76 | 42.30% | 170.14% |
The latest Xencor stock forecast, released on Jun 14, 2024 by Etzer Darout from BMO Capital, set a price target of $32.00, which represents a 53.15% increase from the stock price at the time of the forecast ($20.89), and a 49.05% increase from XNCR last price ($21.47).
Xencor Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $33.67 |
| Last Closing Price | $21.47 | $21.47 | $21.47 |
| Upside/Downside | -100.00% | -100.00% | 56.82% |
In the current month, the average price target of Xencor stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Xencor's last price of $21.47. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 10, 2024 | Wedbush | Buy | Buy | Hold |
| Apr 16, 2024 | Wedbush | Buy | Buy | Hold |
| Apr 16, 2024 | BTIG | Buy | Buy | Hold |
| Feb 28, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 28, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Dec 06, 2022 | Cowen & Co. | - | Outperform | Initialise |
| Oct 13, 2022 | Raymond James | - | Strong Buy | Upgrade |
Xencor's last stock rating was published by BMO Capital on Jun 14, 2024. The company gave XNCR a "Outperform" rating, the same as its previous rate.
Xencor Financial Forecast
Xencor Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $44.69M | $59.16M | $45.52M | $18.96M | $21.61M | $27.30M | - | $85.50M | $154.01M | $19.68M | $67.45M | $33.97M | $41.85M | $35.37M | $13.09M | $32.38M | $3.52M | $21.76M |
| Avg Forecast | $20.57M | $20.57M | $20.57M | $20.57M | $18.93M | $17.55M | $15.97M | $14.67M | $24.45M | $14.60M | $20.00M | $23.07M | $77.63M | $30.01M | $26.25M | $28.72M | $20.07M | $21.05M | $34.01M | $26.14M | $76.29M | $20.74M | $18.51M | $16.01M | $30.51M | $36.01M | $11.71M | $14.64M | $14.31M | $6.72M |
| High Forecast | $31.50M | $31.50M | $31.50M | $31.50M | $28.98M | $26.87M | $24.45M | $22.47M | $37.44M | $32.06M | $30.62M | $35.33M | $121.33M | $45.94M | $40.20M | $43.98M | $30.73M | $32.23M | $34.01M | $54.49M | $159.00M | $43.22M | $38.59M | $33.37M | $63.58M | $75.04M | $24.41M | $30.52M | $29.82M | $14.01M |
| Low Forecast | $4.02M | $4.02M | $4.02M | $4.02M | $3.70M | $3.43M | $3.12M | $2.87M | $4.78M | $1.38M | $3.91M | $4.51M | $11.03M | $5.87M | $5.14M | $5.62M | $3.93M | $4.12M | $34.01M | $5.29M | $15.43M | $4.19M | $3.74M | $3.24M | $6.17M | $7.28M | $2.37M | $2.96M | $2.89M | $1.36M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 8 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.58% | 1.97% | 1.73% | 0.66% | 1.08% | 1.30% | - | 3.27% | 2.02% | 0.95% | 3.64% | 2.12% | 1.37% | 0.98% | 1.12% | 2.21% | 0.25% | 3.24% |
Xencor's average Quarter revenue forecast for Mar 24 based on 4 analysts is $23.07M, with a low forecast of $4.51M, and a high forecast of $35.33M. XNCR's average Quarter revenue forecast represents a -48.37% decrease compared to the company's last Quarter revenue of $44.69M (Dec 23).
Xencor EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 8 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-33.47M | $-18.27M | $-26.00M | $-59.37M | $-42.59M | $-41.41M | - | $32.07M | $75.17M | $-38.20M | $54.00M | $-849.00K | $1.52M | $-11.10M | $-33.58M | $-6.70M | $-25.98M | $-9.50M |
| Avg Forecast | $-6.73M | $-6.73M | $-6.73M | $-6.73M | $-6.19M | $-5.74M | $-5.22M | $-4.80M | $-7.99M | $-4.77M | $-6.54M | $-7.54M | $-25.39M | $-9.81M | $-8.59M | $-9.39M | $-6.56M | $-39.43M | $-11.12M | $-8.55M | $-24.95M | $-35.85M | $-6.05M | $-1.48M | $2.08M | $-11.59M | $-26.19M | $-9.84M | $-22.17M | $-14.31M |
| High Forecast | $-1.32M | $-1.32M | $-1.32M | $-1.32M | $-1.21M | $-1.12M | $-1.02M | $-938.63K | $-1.56M | $-450.22K | $-1.28M | $-1.48M | $-3.61M | $-1.92M | $-1.68M | $-1.84M | $-1.28M | $-31.55M | $-11.12M | $-1.73M | $-5.04M | $-28.68M | $-1.22M | $-1.19M | $2.49M | $-9.27M | $-20.95M | $-7.87M | $-17.74M | $-11.45M |
| Low Forecast | $-10.30M | $-10.30M | $-10.30M | $-10.30M | $-9.48M | $-8.79M | $-7.99M | $-7.35M | $-12.24M | $-10.48M | $-10.01M | $-11.55M | $-39.67M | $-15.02M | $-13.15M | $-14.38M | $-10.05M | $-47.32M | $-11.12M | $-17.82M | $-51.99M | $-43.02M | $-12.62M | $-1.78M | $1.66M | $-13.90M | $-31.43M | $-11.81M | $-26.61M | $-17.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.86% | 3.03% | 6.32% | 6.49% | 1.05% | - | -3.75% | -3.01% | 1.07% | -8.92% | 0.57% | 0.73% | 0.96% | 1.28% | 0.68% | 1.17% | 0.66% |
5 analysts predict XNCR's average Quarter EBITDA for Jul 22 to be $-11.12M, with a high of $-11.12M and a low of $-11.12M. This is -134.67% lower than Xencor's previous annual EBITDA (Mar 22) of $32.07M.
Xencor Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 8 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-19.10M | $-24.27M | $-21.95M | $-59.92M | $-12.04M | $-32.76M | - | $23.59M | $73.06M | $-40.19M | $52.25M | $-2.49M | $-13.69K | $-12.55M | $-35.02M | $-8.07M | $-26.91M | $-10.22M |
| Avg Forecast | $-54.89M | $-54.89M | $-55.51M | $-55.51M | $-63.90M | $-61.48M | $-62.26M | $-60.83M | $-49.11M | $-60.26M | $-51.24M | $90.05M | $-6.54M | $-44.80M | $-49.16M | $71.18M | $-48.62M | $-41.49M | $-30.23M | $56.27M | $927.14M | $-37.72M | $161.11M | $-4.34M | $-18.73K | $-13.10M | $-27.31M | $-11.86M | $-22.97M | $-15.39M |
| High Forecast | $2.51M | $2.51M | $2.54M | $2.54M | $2.92M | $2.81M | $2.84M | $2.78M | $2.24M | $-53.10M | $2.34M | $108.06M | $24.52M | $2.05M | $2.25M | $85.42M | $2.22M | $-33.19M | $-30.23M | $67.53M | $1.11B | $-30.17M | $193.33M | $-3.47M | $-14.99K | $-10.48M | $-21.85M | $-9.48M | $-18.38M | $-12.31M |
| Low Forecast | $-92.80M | $-92.80M | $-93.84M | $-93.84M | $-108.03M | $-103.93M | $-105.25M | $-102.83M | $-83.02M | $-70.41M | $-86.63M | $72.04M | $-34.33M | $-75.73M | $-83.12M | $56.95M | $-82.20M | $-49.79M | $-30.23M | $45.02M | $741.72M | $-45.26M | $128.89M | $-5.21M | $-22.48K | $-15.71M | $-32.78M | $-14.23M | $-27.57M | $-18.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.92% | 0.54% | 0.45% | -0.84% | 0.25% | 0.79% | - | 0.42% | 0.08% | 1.07% | 0.32% | 0.57% | 0.73% | 0.96% | 1.28% | 0.68% | 1.17% | 0.66% |
Xencor's average Quarter net income forecast for Jul 22 is $-30.23M, with a range of $-30.23M to $-30.23M. XNCR's average Quarter net income forecast represents a -228.14% decrease compared to the company's last Quarter net income of $23.59M (Mar 22).
Xencor SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 8 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.27M | $12.49M | $11.46M | $13.95M | $12.75M | $12.37M | - | $11.27M | $11.38M | $10.37M | $8.86M | $8.23M | $7.60M | $7.64M | $7.23M | $7.22M | $6.75M | $6.27M |
| Avg Forecast | $4.42M | $4.42M | $4.42M | $4.42M | $4.07M | $3.78M | $3.43M | $3.16M | $5.26M | $3.14M | $4.30M | $4.96M | $16.70M | $6.45M | $5.65M | $6.18M | $4.32M | $10.71M | $7.32M | $5.62M | $16.41M | $9.73M | $3.98M | $14.36M | $10.40M | $7.97M | $5.64M | $10.60M | $5.76M | $1.45M |
| High Forecast | $6.77M | $6.77M | $6.77M | $6.77M | $6.23M | $5.78M | $5.26M | $4.83M | $8.05M | $6.90M | $6.59M | $7.60M | $26.10M | $9.88M | $8.65M | $9.46M | $6.61M | $12.85M | $7.32M | $11.72M | $34.20M | $11.68M | $8.30M | $17.24M | $12.48M | $9.56M | $6.77M | $12.72M | $6.91M | $3.01M |
| Low Forecast | $865.59K | $865.59K | $865.59K | $865.59K | $796.42K | $738.53K | $671.81K | $617.41K | $1.03M | $296.14K | $841.57K | $970.92K | $2.37M | $1.26M | $1.10M | $1.21M | $844.50K | $8.57M | $7.32M | $1.14M | $3.32M | $7.79M | $805.29K | $11.49M | $8.32M | $6.37M | $4.51M | $8.48M | $4.61M | $292.41K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.94% | 2.03% | 2.26% | 2.95% | 1.16% | - | 2.00% | 0.69% | 1.07% | 2.23% | 0.57% | 0.73% | 0.96% | 1.28% | 0.68% | 1.17% | 4.33% |
Xencor's average Quarter SG&A projection for Mar 24 is $4.96M, based on 4 Wall Street analysts, with a range of $970.92K to $7.60M. The forecast indicates a -67.50% fall compared to XNCR last annual SG&A of $15.27M (Dec 23).
Xencor EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 8 | 5 | 10 | 14 | 8 | 8 | 10 | 13 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.31 | $-0.40 | $-0.37 | $-1.00 | $-0.20 | $-0.55 | - | $0.40 | $1.25 | $-0.69 | $0.90 | $-0.04 | $-0.00 | $-0.22 | $-0.61 | $-0.14 | $-0.47 | $-0.18 |
| Avg Forecast | $-0.89 | $-0.89 | $-0.90 | $-0.90 | $-1.04 | $-1.00 | $-1.01 | $-0.99 | $-0.80 | $-0.98 | $-0.83 | $-0.83 | $-0.11 | $-0.73 | $-0.80 | $-0.66 | $-0.79 | $-0.68 | $-0.49 | $-0.55 | $0.03 | $-0.63 | $-0.59 | $-0.67 | $-0.38 | $-0.22 | $-0.51 | $-0.38 | $-0.41 | $-0.55 |
| High Forecast | $0.04 | $0.04 | $0.04 | $0.04 | $0.05 | $0.05 | $0.05 | $0.05 | $0.04 | $-0.86 | $0.04 | $0.04 | $0.40 | $0.03 | $0.04 | $0.03 | $0.04 | $0.03 | $-0.49 | $0.02 | $0.07 | $0.02 | $0.02 | $0.02 | $0.01 | $0.01 | $0.02 | $0.01 | $0.02 | $0.02 |
| Low Forecast | $-1.50 | $-1.50 | $-1.52 | $-1.52 | $-1.75 | $-1.69 | $-1.71 | $-1.67 | $-1.35 | $-1.14 | $-1.40 | $-1.40 | $-0.56 | $-1.23 | $-1.35 | $-1.12 | $-1.33 | $-1.14 | $-0.49 | $-1.32 | $-0.00 | $-1.52 | $-1.41 | $-1.62 | $-0.91 | $-0.54 | $-1.24 | $-0.91 | $-0.99 | $-1.31 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.92% | 0.55% | 0.46% | 1.51% | 0.25% | 0.81% | - | -0.73% | 44.63% | 1.09% | -1.53% | 0.06% | 0.00% | 0.98% | 1.19% | 0.37% | 1.14% | 0.33% |
According to 5 Wall Street analysts, Xencor's projected average Quarter EPS for Jul 22 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -223.48% decrease compared to XNCR previous annual EPS of $0.40 (Mar 22).
Xencor Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| XNCR | Xencor | $21.47 | $42.60 | 98.42% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
XNCR Forecast FAQ
Is Xencor a good buy?
Yes, according to 6 Wall Street analysts, Xencor (XNCR) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of XNCR's total ratings.
What is XNCR's price target?
Xencor (XNCR) average price target is $42.6 with a range of $31 to $58, implying a 98.42% from its last price of $21.47. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Xencor stock go up soon?
According to Wall Street analysts' prediction for XNCR stock, the company can go up by 98.42% (from the last price of $21.47 to the average price target of $42.6), up by 170.14% based on the highest stock price target, and up by 44.39% based on the lowest stock price target.
Can Xencor stock reach $30?
XNCR's average twelve months analyst stock price target of $42.6 supports the claim that Xencor can reach $30 in the near future.
What are Xencor's analysts' financial forecasts?
Xencor's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $67.11M (high $102.77M, low $13.13M), average EBITDA is $-21.946M (high $-4.294M, low $-33.605M), average net income is $-248M (high $11.35M, low $-420M), average SG&A $14.44M (high $22.1M, low $2.82M), and average EPS is $-4.028 (high $0.184, low $-6.81). XNCR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $82.28M (high $125.99M, low $16.1M), average EBITDA is $-26.906M (high $-5.264M, low $-41.199M), average net income is $-221M (high $10.08M, low $-373M), average SG&A $17.7M (high $27.1M, low $3.46M), and average EPS is $-3.58 (high $0.164, low $-6.052).
Did the XNCR's actual financial results beat the analysts' financial forecasts?
Based on Xencor's last annual report (Dec 2023), the company's revenue was $168.34M, beating the average analysts forecast of $162.62M by 3.52%. Apple's EBITDA was $-138M, beating the average prediction of $-53.176M by 160.41%. The company's net income was $-126M, beating the average estimation of $-29.317M by 330.07%. Apple's SG&A was $53.38M, beating the average forecast of $34.98M by 52.61%. Lastly, the company's EPS was $-2.08, missing the average prediction of $-2.293 by -9.27%. In terms of the last quarterly report (Dec 2023), Xencor's revenue was $44.69M, missing the average analysts' forecast of $77.63M by -42.44%. The company's EBITDA was $-33.466M, beating the average prediction of $-25.386M by 31.83%. Xencor's net income was $-19.1M, beating the average estimation of $-6.54M by 192.07%. The company's SG&A was $15.27M, missing the average forecast of $16.7M by -8.54%. Lastly, the company's EPS was $-0.31, beating the average prediction of $-0.106 by 192.37%